Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review
Metrics: PDF 499 views | Full Text 1253 views | ?
Marco Rubatto1,*, Martina Merli1,*, Gianluca Avallone1, Andrea Agostini1, Luca Mastorino1, Virginia Caliendo1, Amelia Barcellini2, Viviana Vitolo2, Francesca Valvo2, Maria Teresa Fierro1, Simone Ribero1,# and Pietro Quaglino1,#
1 Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy
2 National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy
* Co-first authors
# Co-first senior authors
Keywords: xeroderma pigmentosum; immunotherapy; cemiplimab; hadrontherapy; advanced squamous cell carcinoma
Received: January 04, 2021 Accepted: May 03, 2021 Published: May 25, 2021
Xeroderma Pigmentosum (XP) is a rare genetic disorder with a poor prognosis due to high photosensitivity in affected patients.
Herein, we describe the first case of the use of cemiplimab in a patient with XP, a 19-year-old girl presented with locally advanced squamous cell carcinoma of the right periorbital and nasal region. This treatment has been undertaken after a cycle of proton beam radiotherapy.
Besides, it is reported a description of the few cases in the literature describing the effectiveness of immunotherapy on skin cancers in XP-patients.
This case is in line with those reported, underlining how anti-PD1 monoclonal antibodies may be a promising treatment in this genodermatosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.